BLCM - Bellicum Pharmaceuticals GAAP EPS of -$0.23 revenue of $1M
- Bellicum Pharmaceuticals press release ( NASDAQ: BLCM ): Q3 GAAP EPS of -$0.23.
- Revenue of $1M.
- Bellicum reported cash and cash equivalents totaling $28.8 million as of September 30, 2022, compared to cash, cash equivalents and restricted cash totaling $47.7 million as of December 31, 2021.
For further details see:
Bellicum Pharmaceuticals GAAP EPS of -$0.23, revenue of $1M